本帖最后由 老马 于 2012-1-13 21:20 编辑
/ o9 b/ _9 Q( v- }6 K; S1 |0 x8 S& R2 J4 b# w1 f8 x/ Y
爱必妥和阿瓦斯丁的比较, S5 J3 [( k5 ^) z
7 q, l: |) @- F/ p: u _6 `http://cancergrace.org/lung/2008/08/30/bms099-os-neg// S7 Z" m) r) B. L0 A/ W/ S: H( G! ~/ O
/ h, ^8 a- A3 y: s8 x& M# N+ C4 p: G
; @' g/ E7 x/ m- f0 S
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ X0 u) I& R, A- G9 i==================================================! @% _* b3 A! X1 y1 }* i: S- }; ]7 P
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)5 B# f6 J2 S. p/ q/ _9 U
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 i' ?2 \7 A3 @Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* z% r% P$ @' G! O
|